Publication | Closed Access
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer
61
Citations
15
References
2016
Year
OncologySingle AgentMedicineImmune Checkpoint InhibitorAnti-cancer AgentCdk 4Cancer TreatmentPharmacologyRadiation OncologyPhase 1Cancer Research
| Year | Citations | |
|---|---|---|
Page 1
Page 1